New approaches to the treatment of pancreatic cancer: From tumor-directed therapy to immunotherapy

BioDrugs

Volumn 25, Issue 4, 2011, Pages 207-216

  Lowery, Maeve A ^a   Oreilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anti CTLA 4 monoclonal antibody; Cancer vaccines; Immunotherapies; Pancreatic cancer; Poly(ADP ribose) polymerase inhibitors; Receptor protein tyrosine kinase antagonists

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CANCER ANTIBODY; CANCER VACCINE; CAPECITABINE; CETUXIMAB; CYCLOPHOSPHAMIDE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GANITUMAB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INIPARIB; IPILIMUMAB; IRINOTECAN; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; OXALIPLATIN; PACLITAXEL; PEPTIDE VACCINE; PROSTATE STEM CELL ANTIGEN ANTIBODY; TELOVAC; TERTOMOTIDE; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; VISMODEGIB;

ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIARRHEA; DISTANT METASTASIS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG FORMULATION; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; GENOME ANALYSIS; HUMAN; INTERSTITIAL LUNG DISEASE; MELANOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CANCER VACCINES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; IMMUNOTHERAPY; LEUCOVORIN; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS;

EID: 80051525023     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11592470-000000000-00000     Document Type: Article

References (64)

1. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-6
2. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-7
3. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-13
4. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 2011; 364: 1817-25
5. VonHoff D. Epithelium and stroma: double trouble. Progress in Pancreatic Cancer Session: 101st Annual Meeting of the American Association for Cancer Research (AACR); 2010 Apr 18; Washington, DC
6. Von Hoff DD, Ramanathan R, Borad M, et al. SPARC correlation with response to gemcitabine plus nab-paclitaxel in patients with advanced metastatic pancreatic cancer [abstract no. 4525]. J Clin Oncol 2009; 27 Suppl.
7. Olive K, Jacobetz M, Davidson C, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-61
8. Sidney Kimmel Comprehensive Cancer Center. A phase II study of gemcitabine and nab-paclitaxel in combination withGDC-0449 (Hedgehog inhibitor) in patients with previously untreated metastatic adenocarcinoma of the pancreas [ClinicalTrials.gov identifier NCT01088815].US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: . clinicaltrials.gov [Accessed 2011 Mar 29]
9. Loehr M, Bodoky G, Folsch U, et al. Cationic liposomal paclitaxel in combination with gemcitabine in patients with advanced pancreatic cancer: a phase II trial [abstract no. 4526]. J Clin Oncol 2009; 27 Suppl.
10. Laurent-Puig P, Lievre A, Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009; 15: 1133-9
11. Moore M, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6 (Pubitemid 46972777)
12. Radiation Therapy Oncology Group; National Cancer Institute (NCI). A phase III trial evaluating both erlotinib and chemoradiation as adjuvant treatment for patients with resected head of pancreas adenocarcinoma [ClinicalTrials.gov identifier NCT01013649]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Mar 29]
13. Buchler P, Reber H, Eibl G, et al. Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int J Oncol 2005; 27: 1125-30
14. Safran H, Miner T, Bahary N, et al. Lapatinib and gemcitabine for metastatic pancreatic cancer: a phase II study [abstract no. e15653]. J Clin Oncol 2009; 27 Suppl.
15. Hofmann F, Garca-Echeverra C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005; 10: 1041-7 (Pubitemid 41074142)
16. Amgen. GAMMA-gemcitabine and AMG 479 in metastatic adenocarcinoma of the pancreas [ClinicalTrials.gov identifier NCT01231347]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2011 Mar 29]
17. Beltran PJ, Mitchell P, Moody G. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models [abstract no. 4617]. J Clin Oncol 2008; 26 Suppl.
18. Yendluri V, Wright JR, Coppola D, et al. A small molecule inhibitor of insulinlike growth factor 1 receptor (PQIP) inhibits human pancreatic cancer cell proliferation in vitro and synergizes with erlotinib [abstract no. 184]. ASCO Gastrointestinal Cancers Symposium, 2008 Jan 25-27; Orlando (FL)
19. Southwest Oncology Group. Phase I/II randomized study of gemcitabine hydrochloride and erlotinib hydrochloride with versus without anti-IGF-1R recombinant monoclonal antibody IMC-A12 as first-line therapy in patients with unresectable metastatic pancreatic cancer [ClinicalTrials.gov identifier NCT00617708]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 21]
20. Kindler HL, Richards DA. A placebo-controlled, randomized phase II study of conatumumab (C) or AMG 479 (A) or placebo (P) plus gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (mPC) [abstract no. 4035]. J Clin Oncol 2010 May; 28 (15 Suppl.)
21. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebocontrolled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) [abstract no. 4508]. J Clin Oncol 2007; 25 Suppl.
22. Kim GP, Oberg AL, Foster NR, et al. Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma [abstract no. 4553]. J Clin Oncol 2007; 25 Suppl.
23. Crane CH, Winter K, Regine WF, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: radiation therapy oncology group RTOG 0411. J Clin Oncol 2009; 21: 8529
24. Sanofi-Aventis. Aflibercept compared to placebo in terms of efficacy in patients treated with gemcitabine for metastatic pancreatic cancer [Clinical- Trials.gov identifier NCT00574275]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: [Accessed 2011 Mar 29]
25. Pfizer. Study of gemcitabine plus AG-013736 versus gemcitabine for advanced pancreatic cancer [ClinicalTrials.gov identifier NCT00471146]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Mar 29]
26. Kindler H, Ioka T, Richel D, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011; 12: 256-62
27. Van Cutsem E, Vervenne W, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27: 2231-7
28. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010; 46: 9-20
29. Kyle S, Thomas HD, Mitchell J, et al. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2- defective cancer. Br J Radiol 2008; 81: S6-11
30. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer [abstract no. CRA501]. J Clin Oncol 2009; 27 Suppl.
31. Audeh MW, Penson RT, Friedlander M, et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer [abstract no. 5500]. J Clin Oncol 2009; 27 Suppl.
32. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-9 (Pubitemid 39331153)
33. AstraZeneca, KuDOS Pharmaceuticals Limited. Study to assess the safety & tolerability of a PARP inhibitor in combination with gemcitabine in pancreatic cancer [ClinicalTrials.gov identifier NCT00515866]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Mar 29]
34. Abbott. A study of ABT-888 in combination with carboplatin in subjects with advanced solid tumors [ClinicalTrials.gov identifier NCT01063816]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Mar 29]
35. BiPar Sciences. A phase 1B, open-label, dose escalation study evaluating the safety of BSI-201 in combination with chemotherapeutic regimens in subjects with advanced solid tumors [ClinicalTrials.gov identifier NCT00422682]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Mar 29]
36. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004; 10: 48-54 (Pubitemid 38524698)
37. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61 (Pubitemid 36222930)
38. Hinz S, Pagerols-Raluy L, Oberg HH, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007; 67: 8344-50 (Pubitemid 47395173)
39. US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Mar 29]
40. Weden S, Klemp M, Gladhaug IP, et al. Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 2011; 128: 1120-8
41. Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol. Epub 2010 Aug 3
42. Maki RG, Livingston PO, Lewis JJ, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci 2007; 52: 1964-72 (Pubitemid 47024649)
43. Bernhardt SL, Gjertsen MK, Trachsel S, et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006; 95: 1474-82 (Pubitemid 44863349)
44. Buanes T, Maurel J, Liauw W, et al. A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC) [abstract no. 4601]. J Clin Oncol 2009; 27 Suppl.
45. Royal Liverpool University Hospital. A prospective, phase III, controlled, multicentre, randomised clinical trial comparing combination gemcitabine and capecitabine therapy with concurrent and sequential chemoimmunotherapy using a telomerase vaccine in locally advanced and metastatic pancreatic cancer [ClinicalTrials.gov identifier NCT00425360]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jun 21]
46. Wobser M, Keikavoussi P, Kunzmann V, et al. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006; 55: 1294-8 (Pubitemid 43992055)
47. Julius-Maximilians University. Survivin peptide vaccination for patients with advanced melanoma, pancreatic, colon and cervical cancer [Clinical- Trials.gov identifier NCT00108875]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: [Accessed 2011 Mar 29]
48. Gulley JL, Arlen PM, Tsang KY, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008; 14: 3060-9
49. MediLexicon International Ltd. Therion reports results of phase 3 PANVACVF trial and announces plans for company sale. Medical News Today 2006 Jun 29 [online]. Available from URL: http://www.medicalnewstoday.com/articles/ 46137.php 2006 [Accessed 2011 Mar 29]
50. Immunotherapy for unresectable pancreas cancer: a phase I study of intratumoral recombinant Fowlpox PANVAC (PANVAC-F) plus subcutaneous recombinant vaccinia PANVAC (PANVAC-V), PANVAC-F and recombinant granulocyte-macrophage colony stimulating factor (rH-GMCSF) [ClinicalTrials.gov identifier NCT00669734]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: trials.gov [Accessed 2011 Mar 29]
51. Yoshimura K, Laird LS, Chia CY, et al. Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res 2007; 67: 10058-66 (Pubitemid 47621257)
52. Yoshimura K, Jain A, Allen HE, et al. Selective targeting of anti-tumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res 2006; 66: 1096-104
53. Laheru DA, Jaffee EM. Potential role of tumor vaccines in GI malignancies. Oncology (Williston Park) 2000; 14: 245-56; discussion 259-60, 265
54. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocytemacrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001; 19: 145-56 (Pubitemid 32063491)
55. Lutz E, Yeo CJ, Lillemoe KD, et al. A lethally irradiated allogeneic granulocyte- macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: a phase II trial of safety, efficacy, and immune activation. Ann Surg 2011 Feb; 253 (2): 328-35
56. Laheru D, Yeo C, Biedrzycki B, et al. A safety and efficacy trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene in combination with adjuvant chemoradiotherapy for the treatment of adenocarcinoma of the pancreas [abstract no. 3010]. J Clin Oncol 2007; 25 Suppl.: 18S
57. Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte macrophage colonystimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008; 14: 1455-63 (Pubitemid 351413929)
58. Thomas AM, Santarsiero LM, Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004; 200: 297-306 (Pubitemid 39031249)
59. A randomized three-arm neoadjuvant and adjuvant feasibility and toxicity study of a GM-CSF secreting allogeneic pancreatic cancer vaccine administered either alone or in combination with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide for the treatment of patients with surgically resected adenocarcinoma of the pancreas [Clinical- Trials.gov identifier NCT00727441]. US National Institutes of Health, ClinicalTrials. gov [online]. Available from URL: [Accessed 2011 Mar 29]
60. Hoos A, Ibrahim R, Korman A, et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010; 37: 533-46
61. Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010; 33: 828-33
62. Aglietta M, Barone C, Muliello M.Aphase I dose escalation trial of CP-675206 (tremelimumab) in combination with gemcitabine in patients with chemotherapy- naive metastatic pancreatic cancer [abstract no. 4134]. J Clin Oncol 2010; 28 Suppl.
63. Hoos A, Eggermont AM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102: 1388-97
64. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-22